Dr. Ramalingam Explores Cytotoxics in Lung Cancer

Suresh S. Ramalingam, MD
Published Online: Tuesday, January 22, 2013
Suresh S. Ramalingam, MD, chief of Thoracic Oncology and director of Medical Oncology at Emory University’s Winship Cancer Institute, explains that a number of new cytotoxic drugs are being developed in combination with targeted therapies, such as EGFR inhibitors.

The microtubule inhibitor eribulin mesylate (Halaven) is being examined in combination with the EGFR inhibitor erlotinib in patients with advanced non-small cell lung cancer (NSCLC). Eribulin has shown activity in NSCLC patients and is already approved in metastatic breast cancer leading to the rationale to explore it further in NSCLC.

Ramalingam believes the appeal of investigating newer cytotoxic agents, such as eribulin, is based on how readily these agents work in combination with existing cytotoxics and targeted therapies.

Online CME Activities
Free CME from PER
OncoLogue: Breast Cancer Cases
Update From ASCO: Advances in Immunotherapy for Non–Small Cell Lung Cancer and Melanoma
Updates in Supportive Care From ASCO 2014
Community Practice Connections: Personalization of NSCLC Therapy: Novel Breakthroughs in Patient Care
More Reading
Publications
$auto_registration$